TD Cowen lowered the firm’s price target on Ginkgo Bioworks to $7 from $12 and keeps an Outperform rating on the shares. The firm said the target reduction reflects fewer new program adds and lower revenues however they remain positive on the company’s long-term prospects in Pharma AI and Biosecurity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Cathie Wood’s ARK Investment bought 4.03M shares of Ginkgo Bioworks today
- Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
- Ginkgo Bioworks narrows FY23 revenue view to $250M-$260M from $245M-$260M
- Ginkgo Bioworks reports Q3 EPS (16c), consensus (9c)
- Ginkgo Bioworks options imply 12.2% move in share price post-earnings